These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33864846)

  • 1. Buprenorphine for Chronic Pain in a Pediatric Patient With Sickle-Cell Disease.
    Irwin M; Gunther W; Keefer P; Saul D; Singh SA; Wright J; Smith MA
    J Pain Symptom Manage; 2021 Nov; 62(5):1086-1091. PubMed ID: 33864846
    [No Abstract]   [Full Text] [Related]  

  • 2. "Buprenorphine, It Works so Differently": Adults with Sickle Cell Disease Describe Transitioning to Buprenorphine for Treatment of Chronic Pain.
    Prince E; Loeser P; Early M; Carroll CP; Lanzkron S; Pecker LH
    J Pain; 2024 Mar; 25(3):632-641. PubMed ID: 37742907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of severe chronic pain with methadone in pediatric patients with sickle cell disease.
    LeBlanc Z; Vance C; Payne J; Zhang J; Hilliard L; Lebensburger JD; Howard TH
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27084. PubMed ID: 29749702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world implementation of the David-Carroll buprenorphine protocol for pain management in sickle cell disease.
    Torres C; Galadanci N; Osborn J; Kanter J
    Am J Hematol; 2024 Sep; 99(9):1834-1836. PubMed ID: 38895887
    [No Abstract]   [Full Text] [Related]  

  • 5. Opioid treatment for acute and chronic pain in patients with sickle cell disease.
    Carroll CP
    Neurosci Lett; 2020 Jan; 714():134534. PubMed ID: 31593753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid utilization patterns in United States individuals with sickle cell disease.
    Ballas SK; Kanter J; Agodoa I; Howard R; Wade S; Noxon V; Dampier C
    Am J Hematol; 2018 Oct; 93(10):E345-E347. PubMed ID: 30051929
    [No Abstract]   [Full Text] [Related]  

  • 7. Recommending buprenorphine for pain management.
    Ehrlich AT; Darcq E
    Pain Manag; 2019 Jan; 9(1):13-16. PubMed ID: 30507294
    [No Abstract]   [Full Text] [Related]  

  • 8. Buprenorphine for Chronic Pain: a Systemic Review.
    Fishman MA; Kim PS
    Curr Pain Headache Rep; 2018 Oct; 22(12):83. PubMed ID: 30291571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine in the Treatment of Chronic Pain.
    Rudolf GD
    Phys Med Rehabil Clin N Am; 2020 May; 31(2):195-204. PubMed ID: 32279723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating Chronic Pain with Buprenorphine-The Practical Guide.
    Case AA; Kullgren J; Anwar S; Pedraza S; Davis MP
    Curr Treat Options Oncol; 2021 Nov; 22(12):116. PubMed ID: 34791564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omega-3 fatty acids in sickle cell anemia.
    Pollack S
    Blood; 2013 Mar; 121(12):2366-7. PubMed ID: 23520332
    [No Abstract]   [Full Text] [Related]  

  • 12. How Would You Treat This Patient With Acute and Chronic Pain From Sickle Cell Disease? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Kanjee Z; Achebe MO; Smith WR; Burns RB
    Ann Intern Med; 2022 Apr; 175(4):566-573. PubMed ID: 35404671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambulatory microdose induction of buprenorphine-naloxone in two adolescent patients with sickle cell disease.
    Buchheit BM; Joslin T; Turner HN; Wong TE
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28766. PubMed ID: 33111401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management.
    O'Brien T; Ahn JS; Chye R; Le B; Lu H; Olarte G; Palladini M; Salti A; Shao YY; Yaakup H; Buemio KC; Colin CG; Hadjiat Y
    J Opioid Manag; 2019; 15(2):147-158. PubMed ID: 31343716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clarification on transdermal buprenorphine.
    Dankiewicz EH; Haddox JD
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):415-6. PubMed ID: 25348227
    [No Abstract]   [Full Text] [Related]  

  • 16. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.
    Plosker GL; Lyseng-Williamson KA
    CNS Drugs; 2012 Apr; 26(4):367-73. PubMed ID: 22369187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guideline Promoting Buprenorphine for Treatment of Chronic Pain: Transformative Yet Underdeveloped.
    Cunningham CO; Starrels JL
    Ann Intern Med; 2023 Mar; 176(3):419-420. PubMed ID: 36780656
    [No Abstract]   [Full Text] [Related]  

  • 18. The Complex Association of Daily Opioid Dose with Visits for Pain in Sickle Cell Disease: Tolerance or Treatment-Refractory Pain?
    Prince EJ; Pecker LH; Lanzkron S; Carroll CP
    Pain Med; 2023 Jun; 24(6):703-712. PubMed ID: 36458906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Use After First Opioid Prescription in Children With Sickle Cell Disease.
    Snyder AB; Zhou M; Attell BK; Cohen LL; Carter S; Bock F; Dampier C
    JAMA Pediatr; 2024 Apr; 178(4):408-410. PubMed ID: 38372994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Navigating Ethical Challenges for Pediatric Sickle Cell Pain Management in the Context of the Opioid Epidemic.
    Mulchan SS; Wakefield EO; Martin SR; Ayr-Volta L; Krenicki K; Zempsky WT
    Clin J Pain; 2021 Nov; 38(2):88-94. PubMed ID: 34803155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.